The Orphan Drug Tax Credit is a Proven Catalyst for Investment and Treatment Development

The Orphan Drug Tax Credit is a vital lifeline for rare disease patients and should be protected to preserve hope for the rare disease community. Given that approximately 95% of rare diseases of rare diseases lack an FDA-approved drug, any proposal to reduce the ODTC would have a devastating impact on orphan drug development in the U.S. and on millions of Americans living with a rare disease. We must preserve innovation and not lose the gains that have been made since the passage of the ODA.

Learn more about the Orphan Drug Tax Credit and its role in rare disease treatment development in this overview.